Somatropin - Grandis Biotech

Alternative Names: GrandiTropin T; InfiTropin CR

Latest Information Update: 16 Jul 2007

Price : $50 ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator CSL
Developer Grandis Biotech; InfiMed Therapeutics; Kowa Pharmaceutical
Class Growth hormones; Hormonal replacements; Obesity therapies
Mechanism of Action Somatotropin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Growth disorders; Somatotropin deficiency; Turner's syndrome

Most Recent Events

16 Jul 2013 Biomarkers information updated
16 Jul 2007 Discontinued - Phase-III for Growth disorders in European Union (Parenteral)
16 Jul 2007 Discontinued - Preclinical for Somatotropin deficiency in Japan (Parenteral)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight